Pharmaceuticals company Hester Biosciences announced Q2FY24 & H1FY24 results: 1. Financial Performance: Q2FY24: Revenue from Operations: Rs 704.55 crore, down 4% YoY EBITDA: Rs 132.12 crore, up 4% YoY Profit after Tax (excl. OCI): Rs 40.41 crore, down 39% YoY Earnings Per Share (EPS): Rs 4.75, down 39% YoY H1FY24: Revenue from Operations: Rs 1,583.08 crore, up 28% YoY EBITDA: Rs 275.75 crore, up 37% YoY Profit after Tax (excl. OCI): Rs 107.51 crore, up 6% YoY Earnings Per Share (EPS): Rs 12.64, up 6% YoY 2. Division Performance: - Animal Healthcare division experienced a 16% decline in sales in Q2FY24 due to uneven sales of the Goat Pox Vaccine. - Poultry Healthcare division saw a 4% decrease in overall sales in Q2FY24, with a growth in domestic vaccine sales, but a reduction in export sales. - Petcare division achieved impressive performance, growing 98% in Q2FY24. 3. Subsidiary Performance: - Hester Nepal had a turnover of Rs 7.28 million in Q2FY24, primarily from domestic sales of vaccines, with an overall net loss of Rs 7.05 million. - Hester Africa continued export sales but faced an overall loss of Rs 49.17 million due to foreign exchange fluctuations. - Hester's share of profit in the joint venture entity, Thrishool Exim Limited (Tanzania), increased by 9.86 million in Q2FY24. Result PDF